5-(3-甲氧基苯基)-2H-吡唑-3-胺 | 96799-04-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(3-甲氧基苯基)-2H-吡唑-3-胺
• 中文别名: 3-(3-甲氧基苯)-1H-吡唑-5-胺1HCL；3-(3-甲氧基苯)-1H-吡唑-5-胺；5-(3-甲氧基苯)-1H-吡唑-3-胺
• 英文名称: 3-(3-methoxyphenyl)-1H-pyrazol-5-amine
• 英文别名: 5-(3-methoxyphenyl)-1H-pyrazol-3-amine
• CAS: 96799-04-1
• 化学式: C₁₀H₁₁N₃O
• mdl: MFCD00122783
• 分子量: 189.217
• InChiKey: KTRHWGYZQAKQQQ-UHFFFAOYSA-N

物化性质

• 沸点：
  456.7±35.0 °C(Predicted)
• 密度：
  1.240±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  63.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933199090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-(3-Methoxy-phenyl)-2h-pyrazol-3-ylamine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-(3-Methoxy-phenyl)-2h-pyrazol-3-ylamine
CAS number: 96799-04-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H11N3O
Molecular weight: 189.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(3-甲氧基苯基)-2H-吡唑-3-胺 在 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 4-Ethyl-2-(3-methoxy-phenyl)-4H-pyrazolo[1,5-a]pyrimidin-7-one
  参考文献：
  名称：

  某些吡唑并[1,5-a]嘧啶衍生物的合成及其抗炎特性的研究

  摘要：

  合成了一系列吡唑并[1,5-a]嘧啶-7-酮（1c-17c），以评估在4,7-二氢-4-乙基-的2位结构修饰引起的体内和体外效应。 2-苯基吡唑并[1，5-a]嘧啶-7-一（FPP028）。先前已研究过的该物质是前列腺素生物合成的弱抑制剂，并且是无溃疡的非酸性止痛和抗炎剂。为了更深入地了解这类化合物的作用机理，进行了一些体内试验，例如角叉菜胶诱导的大鼠爪水肿和胸膜炎。体外测试包括对白细胞功能的一些研究，例如超氧化物的产生和髓过氧化物酶的释放。对花生四烯酸，5'-二磷酸腺苷，还研究了血小板活化因子诱导的血小板聚集。根据2位取代基的性质，观察到了不同的抗炎活性。这些差异可能与这些化合物以不同的选择性抑制白三烯和/或前列腺素生物合成的能力有关。4,7-二氢-4-乙基-2（2-噻吩基）吡唑并[1,5-a]嘧啶-7-一（7c）被证明是该合成新化合物中最有趣的化合物，显示出强大的药理活性。体内和体外，

  DOI：

  10.1002/jps.2600820510
• 作为产物：
  描述：

  4-甲氧基苯甲酰基乙腈 在 对甲苯磺酸 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以95%的产率得到5-(3-甲氧基苯基)-2H-吡唑-3-胺
  参考文献：
  名称：

  3,5-二芳基-1 H-吡唑并[3,4- b ]吡啶类作为有效的微管蛋白聚合抑制剂：合理的设计，合成和生物学评估

  摘要：

  通过环系策略设计了一系列新型的3,5-二芳基-1 H-吡唑并[3,4- b ]吡啶类化合物作为针对秋水仙碱位点的微管蛋白聚合抑制剂，并得到了构象分析的支持。一般的化学上不稳定的旋转接头碳原子团被1 H-吡唑并[3,4- b ]吡啶锁定，以避免羰基还原并限制由碳-碳单键旋转引起的分子构象的不稳定性羰基。合成了所有目标化合物，并通过MTT分析评估了其对三种人类癌症细胞系（SGC-7901，A549和HeLa）的抗增殖活性。这些化合物大多数显示出突出的体外效力和该支架13d中最有效的化合物（SGC-7901：IC 50  = 13 nM）可以显着抑制微管蛋白聚合并强烈破坏细胞骨架。分子建模研究的结果表明，13d通过与秋水仙碱位点结合而与微管蛋白相互作用。

  DOI：

  10.1016/j.ejmech.2018.12.053
• 作为试剂：
  描述：

  3-甲氧基苯甲酰基乙腈 、 肼 在 异丙醇 、 5-(3-甲氧基苯基)-2H-吡唑-3-胺 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 5-(3-甲氧基苯基)-2H-吡唑-3-胺
  参考文献：
  名称：

  3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors

  摘要：

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调节、调制和/或抑制异常细胞增殖。

  公开号：

  US07005444B2

文献信息

• Development of Inhibitors against <i>Mycobacterium abscessus</i> tRNA (m¹G37) Methyltransferase (TrmD) Using Fragment-Based Approaches
  作者：Andrew J. Whitehouse、Sherine E. Thomas、Karen P. Brown、Alexander Fanourakis、Daniel S.-H. Chan、M. Daben J. Libardo、Vitor Mendes、Helena I. M. Boshoff、R. Andres Floto、Chris Abell、Tom L. Blundell、Anthony G. Coyne

  DOI：10.1021/acs.jmedchem.9b00809

  日期：2019.8.8

  with improved efficacy. tRNA (m1G37) methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent

  脓肿分枝杆菌 (Mab) 是一种快速增长的多重耐药非结核分枝杆菌，对囊性纤维化和其他已有慢性肺部疾病的患者构成越来越大的威胁。单克隆抗体肺部感染很难治疗，有时甚至不可能治疗，会导致肺功能加速衰退和过早死亡。因此，迫切需要开发具有改善功效的新型抗生素。tRNA (m1G37) 甲基转移酶 (TrmD) 是新型抗生素的一个有前景的靶标。它对于 Mab 和其他分枝杆菌至关重要，可改善核糖体上的读码框维护以防止移码错误。在这项工作中，采用基于片段的方法，合并与活性位点结合的两个片段，然后进行结构引导的精加工，以设计针对 Mab TrmD 的有效纳摩尔抑制剂。其中几种化合物对分枝杆菌物种表现出有希望的活性，除了 Mab 之外，还包括结核分枝杆菌和麻风分枝杆菌，支持使用 TrmD 作为开发抗分枝杆菌化合物的靶点。
• [EN] SULFONYLAMINOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSÉS SULFONYLAMINOPYRIDINE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016001341A1

  公开（公告）日：2016-01-07

  Provided are sulfonylaminopyridine compounds that are inhibitors of ITK kinase, compositions containing these compounds and methods for treating diseases mediated by ITK kinase. In particular, provided are compounds of Formula (I), (II) or (III), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where n, R1, R2, R3, R6 and R7 are defined herein, pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier, adjuvant or vehicle, methods of using the compound or composition in therapy, for example, for treating a disease or condition mediated by ITK kinase in a patient.

  提供了一种磺酰氨基吡啶化合物，它们是ITK激酶的抑制剂，包含这些化合物的组合物以及治疗由ITK激酶介导的疾病的方法。具体来说，提供了Formula (I)、(II)或(III)的化合物，立体异构体、互变异构体、溶剂合物、前药或其药用可接受的盐，其中n、R1、R2、R3、R6和R7在此处定义，包括含有该化合物和药用可接受的载体、辅料或载体的药物组合物，使用该化合物或组合物进行治疗的方法，例如，用于治疗患有由ITK激酶介导的疾病或病况的患者。
• [EN] ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DE RÉCEPTEURS NICOTINIQUES ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：WYETH CORP

  公开号：WO2010009290A1

  公开（公告）日：2010-01-21

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.

  本发明提供了化合物和组合物，制备它们的方法，以及利用它们调节α7烟碱乙酰胆碱受体和/或治疗各种疾病、疾病和症状的方法。所提供的化合物可以影响神经系统、精神病学和/或炎症系统等方面。
• THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE
  申请人：Suzuki Masaki

  公开号：US20150307477A1

  公开（公告）日：2015-10-29

  Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.

  本文描述了利用调节纹状体富集的酪氨酸磷酸酶（STEP）的化合物来治疗疾病的方法。示例疾病包括精神分裂症和认知缺陷。
• 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
  申请人：Allergan, Inc.

  公开号：US06559173B1

  公开（公告）日：2003-05-06

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调控、调节和/或抑制异常细胞增殖。